"Failed" from a business perspective.
Both of these trials were intended to give Novo a product to compete with Eli Lilly. Neither did.
CagriSema failed to reach its target and underperformed Reta results,
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the | A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the...
www.fiercebiotech.com
While it's good to know much higher doses of Sema are safe, triple the dose for a 2.5% median greater weight loss vs 2.4mg, along with a disproportionate increase in sides is nothing to get excited about. What doctor would prescribe this over Tirz?
All they can do with these is drop the price, and say "May not be as good as Zepbound/Reta but it's a better value.", if they do market either.